Levodopa-Carbidopa Intestinal Gel for Sedimentation and Oxidation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of levodopa and carbidopa intestinal gels face challenges such as sedimentation of drug particles during storage and chemical instability, leading to inconsistent dopamine levels in the brain, which are not effectively addressed by existing commercial products like DuoDopa®, limiting their long-term use for treating Parkinson's disease.
Innovation Solution
A pharmaceutical composition comprising levodopa and carbidopa suspended in polymer-based suspending agents with a yield value of at least 0.3 Pa, packaged in an oxygen barrier foil pouch, ensuring physical stability for up to 60 weeks and chemical stability for at least 15 weeks at room temperature, maintaining consistent dopamine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa and carbidopa are co-administered to treat Parkinson's disease, then the L-dopa dose required is reduced and side effects are minimized, but it is difficult to consistently maintain desired dopamine levels in the brain due to the short half-life of L-dopa in plasma
Solution Approach 1:
The gel formulation is prepared in advance with levodopa and carbidopa suspended in a gel matrix, allowing for controlled release over time. This preliminary preparation enables consistent dopamine levels by providing a sustained release mechanism that overcomes the short half-life limitation of L-dopa.
Solution Approach 2:
The intestinal gel formulation provides continuous delivery of levodopa and carbidopa through the gastrointestinal tract. This continuous action maintains steady plasma concentrations and consistent dopamine levels in the brain, addressing the short half-life issue through sustained release rather than intermittent dosing.
2Ease of operation
If a pharmaceutical gel composition is stored at room temperature for long-term administration, then convenience is improved, but physical stability is compromised due to sedimentation of drug particles
Solution Approach 1:
The gel formulation uses specific gelating agents and suspending agents that modify the physical parameters of the system. By adjusting viscosity, yield value, and rheological properties through careful selection of gel components, the formulation achieves physical stability at room temperature without requiring refrigeration, thus maintaining both convenience and stability.
3Reliability
If carbidopa is stored in aqueous gel formulation, then it provides therapeutic benefit, but chemical instability occurs leading to hydrazine formation
Solution Approach 1:
The gel formulation creates a controlled chemical environment that minimizes oxidation and degradation of carbidopa. By using appropriate buffering agents, antioxidants, and pH control in the gel matrix, the formulation reduces the formation of harmful degradation products like hydrazine while maintaining therapeutic effectiveness.
Solution Approach 2:
The gel matrix acts as an intermediary between carbidopa and the external environment. The gel components including buffering agents and protective excipients mediate the chemical environment, preventing direct exposure to conditions that would cause degradation and hydrazine formation while still allowing therapeutic action.
4Reliability
If levodopa and carbidopa are administered continuously via intestinal gel, then dopamine level variability is reduced, but product preparation complexity increases due to sedimentation and stability issues
Solution Approach 1:
The formulation uses a composite gel system combining multiple components including gelating agents, suspending agents, buffering agents, and protective excipients. This composite structure provides both the rheological properties needed for stable suspension and the chemical environment needed to prevent degradation, simplifying preparation while ensuring stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides stable and consistent dopamine levels in the brain, reducing the risk of sedimentation and chemical degradation, thereby effectively treating Parkinson's disease with improved therapeutic efficacy.
Implementation Method 1
levodopa and carbidopa suspended in polymer-based suspending agents
Implementation Method 2
packaged in an oxygen barrier foil pouch, ensuring physical stability for up to 60 weeks and chemical stability for at least 15 weeks at room temperature
Data Source
AI summary
The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.